Recce Pharmaceuticals Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RECEF research report →
Price Chart
About the company
Recce Pharmaceuticals Ltd is a biotechnology firm dedicated to the discovery, development, and commercialization of cutting-edge synthetic anti-infective treatments. The company's operations span major markets, including Australia, the United States, and the United Kingdom. Its primary drug candidate, RECCE 327, is engineered to combat severe blood infections and sepsis caused by E.
- CEO
- James Hamilton-Bray Graham
- IPO
- 2022
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on RECEF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $67.27M
- P/E
- -5.50
- Fwd P/E
- 1.97
- PEG
- -0.30
- P/S
- 0.00
- P/B
- -4.93
- EV/EBITDA
- -4.24
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 84.67%
- ROIC
- 234.09%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-369,367+87.4%
- Op Income
- $-24,004,649
- Net Income
- $-15,505,585+27.6%
- EPS
- $-0.05+40.7%
- OCF Growth
- +49.9%
- FCF Growth
- +49.6%
- 52W High
- $0.60
- 52W Low
- $0.22
- 50D MA
- $0.22
- 200D MA
- $0.22
- Beta
- 0.39
- RSI (14)
- 100
- Avg Volume
- 72
No earnings-call transcripts are available for RECEF yet.
- Free Float
- 53.1%
- Shares Outstanding
- 305.77M
- Float Shares
- 162.23M
Our RECEF coverage
Recent articles, reports, and earnings notes.
No research on RECEF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RECEF report →Snowflake shares surge after Q2 beat, raised guidance
proactiveinvestors.com · Sep 2
Polymarket valuation hits $21bn as Trump Jr's firm leads $1bn round
proactiveinvestors.com · Sep 2
Baidu misses Q2 revenue and earnings estimates as core business slips
proactiveinvestors.com · Aug 18
Bank of England holds rates but three dissenters vote for hike
proactiveinvestors.com · Jul 30
Recce Pharmaceuticals positioned for US$66.9 billion US biodefence strategy
proactiveinvestors.com · Jul 30
Recce Pharmaceuticals advances dual Phase 3 programs and MENA licensing strategy in strong June quarter
proactiveinvestors.com · Jul 21
Twilio faces higher bar heading into quarterly earnings, says Jefferies
proactiveinvestors.com · Jul 21
Halliburton tops Q2 earnings estimates as CEO warns of softer oilfield services market
proactiveinvestors.com · Jul 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.